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Abstract Since the 1990s, hybrid imaging by means of
software and hardware image fusion alike allows the
intrinsic combination of functional and anatomical image
information. This review summarises in three parts the state
of the art of dual-technique imaging with a focus on clinical
applications. We will attempt to highlight selected areas of
potential improvement of combined imaging technologies
and new applications. In this third part, we discuss briefly
the origins of combined positron emission tomography
(PET)/magnetic resonance imaging (MRI). Unlike PET/
computed tomography (CT), PET/MRI started out from
developments in small-animal imaging technology, and,
therefore, we add a section on advances in dual- and multi-
modality imaging technology for small animals. Finally, we
highlight a number of important aspects beyond technology
that should be addressed for a sustained future of hybrid
imaging. In short, we predict that, within 10 years, we may
see all existing multi-modality imaging systems in clinical
routine, including PET/MRI. Despite the current lack of
clinical evidence, integrated PET/MRI may become partic-
ularly important and clinically useful in improved therapy
planning for neurodegenerative diseases and subsequent
response assessment, as well as in complementary loco-
regional oncology imaging. Although desirable, other combi-
nations of imaging systems, such as single-photon emission
computed tomography (SPECT)/MRI may be anticipated, but
will first need to go through the process of viable clinical
prototyping. In the interim, a combination of PET and
ultrasound may become available. As exciting as these new
possible triple-technique—imaging systems sound, we need
to be aware that they have to be technologically feasible,
applicable in clinical routine and cost-effective.
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Small-animal imaging
“Prediction is very difficult, especially if it is about the future.” Niels
Bohr (1885–1962)
Positron emission tomography (PET)/magnetic resonance
imaging (MRI)
Background and reasoning
In view of the success of PET/CT, the expectations for any
new combination, such as PET/MR, are very high. MRI is a
moreversatileimagingtechniquethanCTinthatitmeasuresa
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DOI 10.1007/s13244-011-0085-4number of physiological and metabolic characteristics of
human tissue [1]. MRI goes beyond plain anatomical
imaging by offering a multitude of endogenous contrast
agents and high capability in differentiating soft tissues, as
well as many exogenous contrast media ranging from
gadolinium-based agents to highly specific cellular markers.
Magnetic resonance spectroscopy (MRS), for example,
can be used to dissect the molecular composition of tissues
by applying selective radiofrequency excitation pulses.
Functional processes in living subjects can also be studied
by diffusion-weighted (DW) MRI. Here, the magnetic field,
generated by different gradients, is used to map phase
differences in the MRI signal that are caused by diffusing
molecules. DW-MRI has potential clinical applications
ranging from diagnosing ischaemia, cancer, multiple
sclerosis, or Alzheimer’s disease to general fibre tracking
via diffusion tensor imaging (DTI), and it is not restricted to
the brain. In addition, functional MRI (fMRI) studies can be
performed during the same examination. Functional MRI
studies are frequently based on the BOLD (blood oxygen
level-dependent) effect. This effect describes the fact that
the magnetic properties of oxygenated and deoxygenated
haemoglobin in the blood are different and, therefore,
produce different signals when imaged with T2*-sensitive
MRI sequences. The BOLD effect also has certain
applications in cancer imaging, such as to study tumour
angiogenesis, tumour oxygenation and brain activation in
relevant areas before surgical resection.
Lately, MRI has become a whole-body imaging technique
as a consequence of the introduction of parallel imaging
techniques.Imageacquisitiontimeshavebeenshortened,thus
allowing whole-body MRI examinations with high spatial
resolutioninlessthan1h.Initialresultsshowthatwhole-body
MRI is a promising technique in oncology, especially for the
detection of metastases and haematological malignancies.
In summary, MRI holds great potential for replacing CT
as the complementary technique to PET in dual-technique
tomographs and in selected indications where MRI outper-
forms CT already. In theory, MRI seems a perfect
anatomical complement to PET.
Technical challenges, concepts and methodological aspects
The development of combined PET/MRI systems started in
the late 1990’s. Given the design of standard PET [and
single-photon emission computed tomography (SPECT)]
detectors based on photomultiplier tubes (PMTs), a PET/
MRI configuration is obviously technically more challenging
than the combination of PET (or SPECT) and CT because
phototubes are sensitive even to low magnetic fields (Fig. 1).
MRI demands very high field homogeneity, and the presence
of PET detectors within this field could interfere with the
MRI. Conversely, the PET detectors have to withstand not
only a high static field level (up to 3 T for clinical MRI), but
also the rapidly changing field gradients required by the
imaging process.
Hammer and co-workers were one of the first groups to
address some of these issues in the mid-1990s. They
proposed to place the PET scintillator blocks inside a
clinical MRI and to extract the information from the
scintillator through light guides that are fed into detector
electronics situated outside the primary magnetic field of
the MRI system [2, 3]. In the mid 1990s, Shao and
co-workers developed a small ring of PET detectors 3.8 cm
in diameter for pre-clinical, small animal imaging [4].
Although subsequent prototypes were suggested (e.g. Slates
et al. [5], Pichler et al. [6] and Judenhofer et al. [7]), PET/
MRI was destined to remain in the pre-clinical arena for
another decade [8] until, in 2006, the first simultaneous MR
and PET images of the human brain were acquired [9].
Figure 2 shows existing hardware concepts for clinical
PET/MRI. In essence three approaches exist towards PET/
MRI: separate gantries operated in different rooms (a),
gantries arranged in line with the main scanner axis with a
patient handling system mounted in between (b) and a fully
integrated system (c). The third design, presented in 2006,
and also the most challenging (Fig. 2c), is based on a PET
detector ring designed as an insert that can be placed inside
a Siemens 3-T Trio MR system (Siemens Healthcare). This
prototype system (BrainPET) was intended for brain
imaging only. The PET insert has an internal diameter of
35.5 cm and comprises 192 LSO (lutetium oxyorthosilicate)
detector blocks arranged in six rings. Each LSO block
comprises a 12×12 matrix of 2.5×2.5×20 mm
3 crystals for
an axial field of view (FOV) of 19.25 cm [9]. Each detector
block is directly coupled to a compact 3×3 APD (avalanche
photo diode) array. The point source sensitivity of the PET
system measured with a line source in air is 5.6% and the
spatial resolution is 2.1 mm at the centre of the FOV. No
degradation of the MR images was observed due to the
presence of the PET detectors and no detrimental effect on
the performance of the PET detectors was observed for a
number of standard MR pulse sequences [9, 32].
The co-planar PET/MRI concept (Fig. 2b), first presented
in 2010, is based on a tandem design of a whole-body time-
of-flight (TOF) PET system and a 3-T Philips Achieva MR
system (Philips Healthcare, Cleveland, USA) with a rotating
table platform in between. Through minor modifications of
the PET detector system (e.g. orientation of the PMT, minor
shielding) the PET gantry can be operated in close proximity
to the 3-T MRI system.
The first design was proposed by GE Healthcare in late
2010 and is so far available as prototype technology only.
This design is based on a combination of a dual-technique
PET/CT and a 3-T MRI system, which are operated in
separate, adjacent rooms; patients are shuttled from one
236 Insights Imaging (2011) 2:235–246system to the other without getting off the bed. This
approach substitutes the challenges of hardware integra-
tion for considerable logistical challenges in timing
access to the two systems while minimising patient
motion in between examinations. However, this approach
has been argued as the most cost-effective compared
with fully integrated PET/MRI, based on workflow
aspects and machine utilisation [10].
In an extension to the integrated design concept of
Fig. 2c, a similar system was proposed in late 2010 that
merged a whole-body PET with a 3-T MRI system to
allow for simultaneous whole-body imaging. Just like the
BrainPET PET/MR prototype, this system is based on
LSO-APD PET detector technology, which is integrated
into the MR gradient coil system offering a 60–cm gantry
opening (versus a 35–cm gantry opening for the brain
prototype).
In addition to the technical challenges of combining PET
and MRI, which increase with the amount of PET-MRI
system integration, the necessary attenuation correction
factors (ACFs) for the PET emission data must be derived
from the PET/MRI measurements [11]. While in PET/CT
PET attenuation data can be derived from transforming
available CT transmission images into maps of attenuation
Fig. 1 a Example of photomul-
tiplier tubes (PMT)-bismuth
germanate (BGO) block detector
from a clinical PET system.
Readout is performed using the
PMTs that are connected to the
pixellated scintillator block.
Light sharing is used to
distribute light originating from
a single pixel between the read-
out PMTs (P1-P4). The position
of the incident annihilation
photon event can be calculated
using an Anger-weighting of the
measured signals (b). b Sche-
matics of the detection process
from annihilation to stopping the
annihilation of photons in the
crystal and signal transformation
inside the PMT. c Conventional
PET detectors (see a) work only
outside magnetic fields (B=0).
If a PMT is operated inside a
magnetic field (B>0), then the
multiplier step is distorted and the
readout map severely distorted. d
Avalanche photodiode (APD)-
based detectors are semiconduc-
tors that can be operated in
magnetic fields, even at higher
field strengths. Images courtesy
Prof. B. Pichler, Tübingen
Insights Imaging (2011) 2:235–246 237coefficients at 511 keV, no such transmission data are
available for PET/MRI. This is primarily due to the lack of
physical space to host a transmission source. Second, a
rotating metal-encased transmission source, whether X-ray
tube, rod or point sources would lead to grave cross-talk
effects with the MR magnetic field. And finally, the
available MR images represent, in essence, proton densities
that cannot be directly translated into maps of electron
densities as obtained from CT transmission measurements.
For example, air and cortical bone yield no significantly
measurable MR signal, whereas the difference in their
photon attenuation properties is 2,500 HU on CT images
(Fig. 3). Therefore, PET/MRI requires novel approaches to
MR-based attenuation correction (MR-AC).
Originally, segmentation-based approaches have been
proposed to classify tissues on MR images and to assign
respective attenuation coefficients. This approach seems to
work well in brain imaging [12]. However, MR-based
attenuation correction (MR-AC) in extra-cerebral applica-
tions is much more demanding [13]. Therefore, atlas-based
approaches have been suggested [14] and torso data [15].
The principle of the atlas approach is to align the MRI
acquired for the PET/MRI study with an average MR image
from an atlas comprising pairs of registered MR and CT
data sets. The same transformation determined from the
alignment of the MRI of the patient with the MRI in the
atlas can be applied to the CT volume from the atlas. A
combination of the registered CT image volume and the
patient-specific MRI can be used to generate a pseudo-CT
map of the PET/MRI study from which the ACFs can be
derived [16]. In view of the absence of an MR bone signal,
the bone structures can be extracted from the registered
atlas CT and combined with an MR image segmented for
air and soft tissue.
Combined PET/CT has been clinically very successful
and may well serve as a benchmark for the development of
PET/MRI. However, despite the success and wide distribu-
tion of PET/CT, there are some shortcomings in the use of
CT as the anatomical complement to PET. CT uses a source
of ionising radiation for imaging and, therefore, adds
significant radiation dose to the overall examination [17],
which may raise concerns in selected populations like
adolescents and women [18]. Further, CT provides com-
paratively low soft-tissue contrast, which is exacerbated
when CT contrast material is being used. MRI, on the other
hand, does not suffer from these two major disadvantages
and, in addition, offers more advanced functional imaging
information, such as DWI or MRS, without adding to the
overall radiation exposure burden. Other safety concerns
do, however, apply to MRI and PET/MRI as discussed by
Brix et al. [19] and mandate the close observation of local
heat tolerance effects in response to specific absorption
rates (SAR) from radiofrequency (RF) exposure and careful
pre-examination patient interviews on the presence or
Fig. 2 Different designs for combined clinical PET/MR systems: (A)
patients can be shuttled between separate MR and PET(/CT) systems
operated in different rooms, (B) patients are positioned on a common
table platform between stationary PET and MR systems; the delay
between the MR- and PET-examination is reduced (Philips Health-
care), and (C) patients are positioned inside an integrated PET/MR
gantry (Siemens Healthcare) with a PET insert that is mounted within
a whole-body MR offering simultaneous PET/MR acquisitions
238 Insights Imaging (2011) 2:235–246absence of passive implants, which may interfere with the
MRI protocol, or disqualify the patient from this examina-
tion all together.
Clinical expectations for PET/MRI
The combination of PETand MRI in a single imaging system
has the potential to become the ultimate multi-modality
imaging technology, combining anatomical, functional, met-
abolic and multi-parametric imaging. Nonetheless, it is
difficult to propose clinical applications of combined PET/
MRI at this stage, where first prototype systems are being
validated in clinical and research settings [20]. Given the fact
that numerous studies exist on the use of retrospectively
aligned PET and MRI (as well as SPECT and MRI), it is fair
to say that hardware-fusion PET/MRI has the potential to
dominate over standalone imaging in certain areas of non-
invasive imaging [21].
PET/MR in neurology The potential areas of application of
combined PET/MRI extend far beyond high-contrast image
fusion. Brain studies, for example, benefit greatly from the
additional morphological information provided by MRI
(Fig. 4). Combined amino acid PET and MRI is likely to
enhance the diagnostic sensitivity for gliomas and may
allow a closer correlation between the tracer uptake and the
metabolic changes (e.g. choline peaks in MR spectroscopy)
in the neoplastic tissue [22]. Likewise, arterial spin-
Fig. 3 MR-based attenuation correction is demanding as the
appearance of air (turquoise arrow) and bone (blue arrow)o nM R
images is very similar despite their significantly different attenuation
coefficients for ionising radiation (see CT, top)
Fig. 4 a Patient with
meningioma in the right
frontal lobe. Axial MR and
simultaneous PET/MR images
through the lesion: T2-weighted
MRI,
68Ga-DOTATOC PET.
b A 42-year-old man with a
neurocytoma. PET/MR images
were acquired simultaneously
following injections of
11C-methionine (left). Simulta-
neously acquired chemical shift
imaging MRS provides a map of
the choline to N-acetyl-aspartate
ratio (centre). Simultaneous
diffusion tensor imaging (DTI)
shows the clear relationship
with the adjacent optic radiation.
Cases courtesy of Drs. Boss,
Bisdas and Schwenzer (UH
Tübingen, Department of
Radiology)
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occurring in low-grade gliomas may be studied in conjunc-
tion with each PET-tracer image to establish reliable disease
markers. Consequently, the “wait-and-see” approach to
low-grade gliomas may be optimised with regard to the
timing and extent of surgery. For the diagnosis of
degenerative and neoplastic diseases, DWI-MRI helps
overcome the shortcomings of morphology imaging only.
Contrast-enhanced dynamic MRI, which may play a more
decisive role for therapy outcome in the future, may now be
compared with the PET-tracer kinetics as the “gold
standard”. Boss and co-workers recently evaluated simul-
taneous PET/MRI for assessing intracranial tumours using
11C-methionine or
68Ga-DOTATOC (Fig. 4a). They dem-
onstrated image quality and quantitative data achieved from
PET/MRI to be similar to that using PET/CT [23]. While
several of the above aspects await further clinical testing,
integrated PET/MRI appears to have great potential in
neuroscience research (Fig. 4b), particularly for multi-
parametric analysis of complex functions in neural net-
works, for the imaging of complex molecular processes of
gene transfer and cell transplantation and for translational
research from pre-clinical into clinical use [24].
PET/MRI in oncology: PET/MRI may be useful for extra-
cerebral oncology applications, but a key application has
yet to be found. In an early study from 2003, Antoch and
co-workers compared whole-body FDG-PET/CT and multi-
station MRI in a heterogeneous group of cancer patients
and concluded that FDG-PET/CT performed better in
overall TNM staging than MRI and, therefore, should be
recommended as a possible first-line technique for whole-
body tumour staging [25]. In a recent review, Antoch and
Bockisch summarised key studies from the literature and
their own experience [26] and conclude that PET/MRI may
be expected to be more accurate than PET/CT for T-staging
in all indications in which MRI is more accurate than CT,
while similar accuracies are to be expected for N-staging.
For M-staging, potential advantages of PET/MRI will
depend on the site of the metastases. Other extra-cerebral
applications of PET/MRI are currently being assessed, but
no real hypothesis can yet be made with regard to the future
clinical potential.
One of the primary strengths of MRI is its ability to
provide anatomical detail in addition to detecting abnor-
malities within bony structures (e.g. marrow, joint spaces).
[
18F]-FDG PET is useful in the diagnosis of acute infections
and is an accurate imaging technique to exclude the
diagnosis of osteomyelitis. When combined and clinically
available, PET/MRI may provide a more accurate diagnosis
of patients with osteomyelitis including those with compli-
cated diabetic foot disease.
Some people argue that PET/MRI will substitute PET/
CT for assessing the therapeutic success of treatments for
chronic diseases, which requires repeated whole-body
assessment of the extent of the disease, relapse, complica-
tions and concomitant diseases [20].
PET/MRI in cardiology Finally, cardiac applications have
started to become the focus of attention of PET/MR
adopters [27]. Historically, cardiac imaging has been a
domain of research where one imaging technique would be
replaced by another depending on the preferences and
loyalties of the cardiac imaging specialists. However,
Nekolla and co-workers discussed a few scenarios where
combined PET/MR cardiac imaging may establish a new
stage of cardiac diagnosis [27]. Combining PET with
cardiac MRI and whole-body MR angiography may enable
detection and differentiation of vulnerable plaques. The
combination of late-enhancement MRI and [
18F]-FDG
uptake within a single imaging examination may expand
the use of cardiac imaging. Initial studies combining MR
spectroscopy with PET have already been performed on
isolated perfused rat hearts, but may also enhance cardiac
PET/MR studies involving cardiac stress simultaneously
assessed with PET and MRI. Dual functional studies
correlating the same parameters (e.g. perfusion in PET with
radioactive water or ammonia and in MRI using arterial
spin labelling or MRI contrast agents) can help to cross-
correlate and validate different acquisition techniques. PET
tracer uptake, or PET perfusion, can be correlated with the
MRI BOLD effect. Because of the large number of potential
PET probes and the various functional imaging capabilities of
MRI, the number of possible combinations for molecular
imaging readouts is virtually unlimited. Simultaneously
acquired PET and MRI data will allow accurate motion
correction, particularly in cardiology, but also in the accurate
detection of lesions in the abdomen or thorax [11].
Methodological challenges
Whole-body PET/MRI will become a key technological
development in medical imaging technologies. Thus,
prototype testing and validation studies today must be
aimed at demonstrating reproducible imaging results with
PET/MRI first. This entails accurate quantification, which,
given the challenges of MR-based attenuation correction
[11], is still not resolved. In this regard, ultra-short echo
time (UTE) pulse sequences are being considered as part of
an integrated PET/MRI examination in order to generate a
signal from bone and, thus, provide means of better
segmenting bone from non-bone tissues during the course
of MR-AC. However, UTE sequences are known to be
240 Insights Imaging (2011) 2:235–246somewhat lengthy and, therefore, their adoption may be
restricted by the overall duration of the study [28].
Clinically validated MR-AC methods must address
adequate transformation of MRI pixel value information
into appropriate PET attenuation values. In addition, MR
image distortions must be detected, traced and, if possible,
corrected during MR-AC. Such distortions include, for
example, truncation and fold-in effects. Further, the
presence of MR surface coils and positioning aids must
be accounted for, both contributing to overall attenuation of
the emission signal [15, 29–31].
In addition, cross-talk effects between MR gradients and
PET electronics must be assessed under clinical imaging
conditions. Finally, adequate workflow protocols must be
designed and tested for a variety of clinical indications [23,
32, 33].
The question of sequential (Fig. 2a, b) or simultaneous
(Fig. 2c) PET/MRI is the subject of an ongoing debate.
From a technical perspective, simultaneous imaging allows
for a number of advanced data processing steps that are not
possible in sequential PET/MRI (and PET/CT imaging).
This includes motion correction for involuntary patient
motion and any subsequent quantification that may be
biased from patient motion during the examination. To
correct for patient motion, special MRI sequences can be
applied by either one-dimensional navigator images or in
two to three dimensions to detect the motion of the subject.
Ideally, these protocols should be combined with the MRI
sequence already running to provide motion information
about the subject in intervals as short as 1 s.
The overall advantage of truly simultaneous PET/MRI is
that the same subject undergoes imaging at the same time
with identical environmental parameters and stimuli. It is
likely that such functional studies will further push the
limits of basic biological research and will open new realms
for studying biology in vivo.
Interestingly, there is potentially an immediate benefit
for PET/CT from the ongoing development of PET/MRI.
Studies by Kolb and co-workers have shown the large
potential for novel types of APD [Geiger-APD (G-APD)]
as light sensors for novel PET detectors. They can be
operated with simpler electronics than those needed for
APDs that are operated in linear mode; neither low-noise
and charge-sensitive preamplifiers nor elaborate shielding
is required. Further advantages of G-APDs over PMTs
include their compactness, low operation voltages and
insensitivity to strong magnetic fields [34]. It could be
argued that G-APD-based detector designs, originally
developed for PET/MRI, may eventually replace the
PMT-based detectors in PET/CT systems and further
stimulate the search for a common detector for both CT
and PET [35].
Small animal imaging systems
Over the past decade we have witnessed a breathtaking
increase in applications of molecular imaging instrumenta-
tion. Non-invasive, small-animal imaging, in particular, has
excelled in catalysing molecular research and supporting
translational research [36, 37]. Similar to human imaging,
small-animal imaging systems were proposed to combine
nuclear medicine technology with CT or MRI, thus
providing co-registered functional and anatomical informa-
tion, and to expand on the spatial coverage and sensitivity
[38]. Figure 5 summarises a selection of dual- and triple-
technique small animal imaging systems available today.
However, the potential of small-animal imaging goes
beyond detecting anatomical details or abnormal changes in
morphology using high-resolution CT or MRI, and it
extends towards revealing complex biochemical pathways
or quantitative measurements of receptor, transporter or
gene expression [39]. Functional imaging applications rely
on methodologies like PET, SPECT or optical imaging
(OI), providing excellent sensitivity to track biomolecules
labelled with a radioactive isotope- or light-emitting
marker. Nonetheless, it is not only the optical or nuclear
methods that are able to provide functional information;
fMRI and MRS have evolved to become powerful tools for
detecting changes in blood flow, tissue oxygenation or
concentrations of endogenous molecules such as lactate,
choline or N-acetyl-aspartate.
A dual-technique imaging combination for pre-clinical
applicationsthathasreceivedacomparativelylargeamountof
attention is PET/MRI. Interestingly, pre-clinical PET/MRI
developments preceded clinical developments for a combina-
tion of PET and MRI [8], unlike PET/CT or SPECT/CT.
Small-animal PET/MRI offers a number of advantages for
pre-clinical studies [40], starting from significantly reduced
exposure of the animal, thus paving the way for multiple
repeat studies, the complementary acquisition of anatomical
and multi-parametric image information through the use of
MRI and much increased soft tissue contrast, making it
easier to assess metabolic disease patterns in live animals.
Judenhofer and co-workers have demonstrated the
feasibility of simultaneous small animal PET/MRI [41],
and perhaps these types of dual-technique imaging systems
will soon replace pre-clinical PET or PET/CT in dedicated
small animal research laboratories. Further reasoning is
provided by Wagenaar et al. [42]: “Simultaneous imaging is
probably more important in the animal imaging domain than
in clinical imaging. … small-animal volumes are ten– to
1,000-times smaller, while heart … and respiratory rate …
are up to ten-times higher. This means that a biological
process that might develop in minutes to hours in humans
can be over in seconds for a mouse …”.
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adopted, making use of the wide range of radiopharma-
ceuticals that can be produced independently of a cyclotron.
Other imaging combinations
Multi-modality imaging with PET/CT and SPECT/CT has
become commonplace in clinical practice and in pre-
clinical and basic biomedical research. But clinical multi-
modality imaging is not only limited to PET/CT, SPECT/
CT and PET/MRI, other imaging systems are currently in
the design or exploratory phase (Fig. 6). The focus is
generally on application-specific tasks such as imaging of
breast and prostate. Examples are discussed briefly by
Townsend [43] and include a combination of scintigraphy
and mammography to reduce the false-positive rates from
standard mammography, of three-dimensional (3D) CT
breast imaging with SPECT or PET.
Recent advances in dedicated breast CT technology
suggest that 3D mammograms are now possible, with no
more radiation dose than from a two-view mammogram
[44]. First studies indicate that the addition of intravenous
contrast medium improved detection even further, and
tumours that had not been seen with conventional
mammography became visible. Some believe that by
combining positron emission mammography (PEM) with
dedicated CT, or even dynamic contrast-enhanced (DCE)
MRI, it should soon be possible to detect tumours as small
as 1 mm. The combination of ultrasound with other
imaging techniques, such as conventional mammography
and PET, has also gained increased attention from clinical
researchers.
As some clinical multi-modality instrumentation origi-
nates from the pre-clinical domain, it is worth noting that
there is commercial development of at least one SPECT/
MR device for small animal imaging [42, 45]. If a demand
exists, this may eventually lead to a clinical SPECT/MR
design.
Presently, the combination of PET or SPECT with MRI is
an area of active prototyping, while the feasibility of other,
perhaps less obvious combinations, including CT/MRI and
PET/optical are also being studied [46]. In addition to the
integration of the instrumentation, there are parallel develop-
ments in synthesising imaging agents that can be viewed by
multiple imaging techniques [46].
Other factors
The future of hybrid imaging does not depend solely on the
talents of system engineers and the drive of clinicians to
make diagnosis more accurate through the adoption of more
and more accurate imaging techniques. As the complexity
of non-invasive diagnostic tools increases, so does the need
for properly trained imaging experts.
Today, a decade after the first introduction of PET/CT,
which originated from ideas raised in the realms of nuclear
medicine, we see a large portion of PET/CT being
employed merely as PET in combination with low-dose
Fig. 5 Different design concepts for dual- and triple-technique imaging systems for pre-clinical applications. In general, system designs are
similar to clinical dual-technique imaging systems even for the docking triple-technique system shown in the right panel
242 Insights Imaging (2011) 2:235–246CT to provide some anatomical background information
[53]. This illustrates an important aspect of today’s PET/
CT, in that it is not always considered and utilised as a new
imaging technique, which is partly related to inter-
disciplinary preferences and the lack of training. Therefore,
joint efforts are promoted by the radiology and nuclear
medicine imaging associations to provide sufficient training
for combined imaging to young radiology professionals,
making it very clear that “EANM and ESR recognise [that
it] is important to provide adequate and appropriate training
in the two disciplines in order to offer a proper service to
the patient using hybrid systems. …” [47].
However, adequate training alone is not sufficient to
promote and adopt, where applicable, new hybrid imaging
technology. Concessions have to be made for the vastly
increased amount of data arising both from increased patient
throughput as well as from the wealth of imaging information
from a combined examination. The latter holds true in
particular for PET/MRI examinations. It is assumed that there
will be an 140% increase in imaging examinations by 2020,
and any advance in imaging technology must be matched by
adequate advances in image assessment, which may support
the use of computer-assisted image review tools. First
approaches were tested in PET/CTwith limited success [48].
Further, the adoption of new dual imaging techniques
should be paired with the introduction of imaging guide-
lines [49–52]. A first evaluation of the adherence to PET/
CT guidelines has revealed surprisingly large deviations
from guideline recommendations [53], which are related to
deviations among guideline recommendations themselves
and the lack of interest and knowledge in adopting
standardised imaging protocols.
Finally, it is easily observed that reimbursement rates for
dual imaging techniques differ widely internationally, even
among industrialised countries [54]. Duplication of proce-
dures and over-use of high-end procedures in situations
where they add little clinical value has driven up technology
spending[55]. While enthusiasm for new technologies grows
quickly the adoption and reimbursement of these technolo-
gies in the future may be restricted and decided upon more
carefully after sufficient technology assessment [56]o rc o s t -
benefit calculations [57].
The future of hybrid imaging: personal perspective
Multi-modality imaging instrumentation has evolved
dramatically during the past decade. Looking back to the
year 2000, it is doubtful that one could have predicted the
rapid clinical and commercial adoption of PET/CT, or the
successful combination of SPECT with high-performance
CT, or the steadily increasing clinical interest in combining
MRI with PET. PET/CT is now well established in the
management of oncology patients, and the future will
Fig. 6 Alternative combinations of imaging techniques in prototype designs and research testing: (a) scintimmamography imaging [58], (b)
combined X-ray/ultrasound imaging [59], (c) mammotomography [60] and (d) SPECT/MRI [42]
Insights Imaging (2011) 2:235–246 243undoubtedly include continuing incremental advances in
CT and PET instrumentation. A major contribution is,
however, expected from the development and clinical
introduction of new PET imaging tracers. These biomarkers
will likely not replace FDG as a first-line imaging
approach, but instead offer increased specificity and
sensitivity in specific diseases and improved monitoring
of therapy response; the choice of biomarker will be guided
by personalised assessment of disease that includes genetic
factors.
SPECT, and more recently SPECT/CT, is well estab-
lished in the clinic, with an extensive range of labelled
pharmaceuticals and the future is likely to involve detector
developments in specific areas such as cardiology, and
more quantitative methodology. Despite the increased cost
of incorporating CT, physicians will likely prefer to read
SPECT with CT rather than SPECT without CT—the CT
very much removes the “unclear” from the study.
In these times of greater economic hardship and
increasing radiation awareness, any predictions for the
future must take into consideration both cost-effectiveness
and radiation dose. The impressive advances in imaging
technology of the past decade came at a cost, but at what
point do these advances becomes cost-effective? Whole-
body PET examinations that took 1 h at the start of the last
decade now take 5 min on PET/CT; the actual imaging
takes only a fraction of the time needed for patient
preparation and positioning or reporting the study.
The commendable drive to reduce radiation exposure to
patients has turned attention to the combination of PET
with MRI, a combination that represents substantial
technical challenges beyond those of PET/CT. While these
challenges have been overcome to a greater extent in the
pre-clinical arena, not surprisingly combined PET/MRI is
now eagerly awaited in the clinic. Indeed, the pre-clinical
PET/MRI work can now be seen as an incubator for clinical
design. So, will the coming decade witness the replacement
of PET/CT by PET/MRI? Some believe it will, just as in
the 1980s there were those who predicted that MRI would
replace CT within 5 years. Of course that never happened,
as both techniques have strengths and weaknesses and they
have each found their niche in the medical imaging
armamentarium. The same is likely true of PET/CT and
PET/MRI—the technical challenges will be solved and
simultaneous acquisition of MRI and PET will undoubtedly
open new doors in clinical research and eventually also in
the clinic.
The radiation dose to the patient incurred by PET,
SPECT and CT is clearly an issue. Although the ALARA
(as low as reasonably achievable) principle is sound advice,
there are clearly groups of cancer-sufferers such as those in
children and young adults where the probability of inducing
a second, radiation-associated cancer exceeds the benefits
that can be accrued from the study. Different imaging
strategies should then be adopted, such as MRI, optical
imagingorultrasound.Thenextdecadeislikelytoseenuclear
imaging devices of greater sensitivity that can operate with
even lower doses of injected activity, and more effective use
madeoftheradiationincurredwithmulti-sliceCTsystems.As
longasdiseasessuchascanceranddementiaremainprimarily
diseases of the elderly, the benefits of nuclear and X-ray
imaging will largely outweigh the risks.
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